HIV Prevalence and HIV Screening History Among a Veterans Association Cohort of People with Opioid and Alcohol Use Disorders

• Published in: Journal of general internal medicine : JGIM 2024-02, Vol.39 (3), p.403-410
• Main Authors: McCann, Nicole C., Davenport, Michael J., Mandavia, Amar D., Stein, Michael D., Livingston, Nicholas A.
• Format: Article
• Language: English
• Subjects: Alcohol use; Alcoholism - diagnosis; Alcoholism - epidemiology; Analgesics, Opioid; Antiretroviral agents; Antiretroviral therapy; Drug abuse; Drug addiction; Drug use; Electronic health records; Electronic medical records; Ethnicity; HIV; HIV Infections - diagnosis; HIV Infections - epidemiology; Human immunodeficiency virus; Humans; Internal Medicine; Medicine; Medicine & Public Health; Minority & ethnic groups; Narcotics; Opioid-Related Disorders; Opioids; Original Research; Prevalence; Race; Retrospective Studies; Subgroups; Substance use; Substance-Related Disorders - epidemiology; United States - epidemiology; United States Department of Veterans Affairs; Veterans
• ISSN: 0884-8734; 1525-1497
• DOI: 10.1007/s11606-023-08452-5

Background Veterans face high risk for HIV and substance use, and thus could be disproportionately impacted by the HIV and substance use disorder (SUD) “syndemic.” HIV prevalence among veterans with SUD is unknown. Objective To project HIV prevalence and lifetime HIV screening history among US veterans with alcohol use disorder (AUD), opioid use disorder (OUD), or both. Design We conducted a retrospective cohort analysis using national Veterans Health Administration (VHA) data. Participants We selected three cohorts of veterans with SUD: (1) AUD, (2) OUD, and (3) AUD/OUD. Included veterans had ICD codes for AUD/OUD from 2016 to 2022 recorded in VHA electronic medical records, sourced from the VA Corporate Data Warehouse (CDW). Main Measures We estimated HIV prevalence by dividing the number of veterans who met two out of three criteria (codes for HIV diagnosis, antiretroviral therapy, or HIV screening/monitoring) by the total number of veterans in each cohort. We also estimated lifetime HIV screening history (as documented in VHA data) by cohort. We reported HIV prevalence and screening history by cohort and across demographic/clinical subgroups. Key Results Our sample included 669,595 veterans with AUD, 63,787 with OUD, and 57,015 with AUD/OUD. HIV prevalence was highest in the AUD/OUD cohort (3.9%), followed by the OUD (2.1%) and AUD (1.1%) cohorts. Veterans of Black race and Hispanic/Latinx ethnicity, with HCV diagnoses, and aged 50–64 had the highest HIV prevalence in all cohorts. Overall, 12.8%, 29.1%, and 33.1% of the AUD/OUD, OUD, and AUD cohorts did not have history of HIV screening, respectively. Conclusions HIV prevalence was high in all SUD cohorts, and was highest among veterans with AUD/OUD, with disparities by race/ethnicity and age. A substantial portion of veterans had not received HIV screening in the VHA. Findings highlight room for improvement in HIV prevention and screening services for veterans with SUD.